You are here

Vyepti

Lundbeck ups guidance on higher expectations for Rexulti, Vyepti

First Word Pharma

Tue, 08/20/24 - 11:50 am

Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses

Fierce Pharma

Tue, 01/23/24 - 11:08 am

Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled

Fierce Pharma

Thu, 08/18/22 - 12:32 pm

Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility

Endpoints

Fri, 11/12/21 - 10:39 am

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

Endpoints

Sat, 02/22/20 - 11:29 pm